To capitalize on the anti-tumor potential of IL-15, we generated a therapeutic fusion protein (KD033), combining a proprietary high affinity human-PD-L1 antibody (or mouse-PD-L1 surrogate antibody (KD033-surrogate)) with human IL-15. The gene discussed is IL15; the disease is neoplasm.